PL4048284T3 - Metoda leczenia nowotworów - Google Patents

Metoda leczenia nowotworów

Info

Publication number
PL4048284T3
PL4048284T3 PL20878437.1T PL20878437T PL4048284T3 PL 4048284 T3 PL4048284 T3 PL 4048284T3 PL 20878437 T PL20878437 T PL 20878437T PL 4048284 T3 PL4048284 T3 PL 4048284T3
Authority
PL
Poland
Prior art keywords
treating cancers
cancers
treating
Prior art date
Application number
PL20878437.1T
Other languages
English (en)
Other versions
PL4048284T4 (pl
Inventor
Hung-Kun Hsu
Original Assignee
Acura Nanomedicine Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acura Nanomedicine Corporation filed Critical Acura Nanomedicine Corporation
Publication of PL4048284T3 publication Critical patent/PL4048284T3/pl
Publication of PL4048284T4 publication Critical patent/PL4048284T4/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20878437.1T 2019-10-21 2020-10-20 Metoda leczenia nowotworów PL4048284T4 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962923631P 2019-10-21 2019-10-21
US201962923629P 2019-10-21 2019-10-21
PCT/CN2020/122269 WO2021078126A1 (en) 2019-10-21 2020-10-20 Method for treating cancers

Publications (2)

Publication Number Publication Date
PL4048284T3 true PL4048284T3 (pl) 2025-11-03
PL4048284T4 PL4048284T4 (pl) 2025-11-03

Family

ID=75619656

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20878437.1T PL4048284T4 (pl) 2019-10-21 2020-10-20 Metoda leczenia nowotworów

Country Status (10)

Country Link
US (2) US12419864B2 (pl)
EP (1) EP4048284B1 (pl)
JP (1) JP7568309B2 (pl)
KR (1) KR20220066938A (pl)
CN (1) CN114585369B (pl)
AU (1) AU2020369741B2 (pl)
ES (1) ES3035147T3 (pl)
PL (1) PL4048284T4 (pl)
TW (1) TWI826738B (pl)
WO (1) WO2021078126A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230061465A (ko) 2020-09-04 2023-05-08 엘랑코 유에스 인코포레이티드 기호성 제형
CN114601833A (zh) * 2022-04-02 2022-06-10 北京大学口腔医学院 一种治疗肿瘤的化学药物组合
WO2024242538A1 (ko) * 2023-05-19 2024-11-28 국립암센터 이버멕틴 및 항암제를 포함하는 암 예방 또는 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008522984A (ja) * 2004-12-06 2008-07-03 ニューサウス イノベイションズ ピーティーワイ リミテッド 癌の処置
KR101707669B1 (ko) * 2008-04-17 2017-02-16 더 존스 홉킨스 유니버시티 약제-내성 종양에서 화학요법제 활성을 증강시키는 on01910.na
CN104164471A (zh) * 2013-11-04 2014-11-26 复旦大学 基于细胞自噬的抗肿瘤药物的筛选方法

Also Published As

Publication number Publication date
ES3035147T3 (en) 2025-08-29
AU2020369741B2 (en) 2024-06-13
EP4048284C0 (en) 2025-03-19
US20250375422A1 (en) 2025-12-11
JP2022553298A (ja) 2022-12-22
EP4048284A1 (en) 2022-08-31
TWI826738B (zh) 2023-12-21
CN114585369B (zh) 2024-09-13
CA3157841A1 (en) 2021-04-29
NZ787377A (en) 2025-02-28
WO2021078126A1 (en) 2021-04-29
AU2020369741A1 (en) 2022-05-12
EP4048284B1 (en) 2025-03-19
CN114585369A (zh) 2022-06-03
JP7568309B2 (ja) 2024-10-16
KR20220066938A (ko) 2022-05-24
PL4048284T4 (pl) 2025-11-03
EP4048284A4 (en) 2023-11-01
TW202128151A (zh) 2021-08-01
US12419864B2 (en) 2025-09-23
US20220387391A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
IL287907A (en) Cancer treatment methods
IL304275A (en) Cancer treatment methods
IL312680A (en) Cancer treatment methods
IL290454A (en) Method of treating kras-associated cancers
ZA201706616B (en) Method for treating cancer
EP3641770A4 (en) CANCER TREATMENT METHODS
IL257691A (en) A method for treating cancer
SG11202100682YA (en) Method for treating epilepsy
IL280800A (en) A method for treating pancreatic cancer
SI4034122T1 (sl) Postopki za zdravljenje hiperfenilalaninemije
IL287210A (en) Preparations for the treatment of tumors
PL3638630T3 (pl) Sposób obróbki szlamu
PL4048284T4 (pl) Metoda leczenia nowotworów
EP3988175A4 (en) Method for treating malignant tumor
IL289811A (en) A method for treating cancer
SG11202010528XA (en) Combinations for treating cancer
GB201909468D0 (en) Compounds for treating cancer
SG10201508795XA (en) Method for treating cancer
IL284668A (en) Methods of treating schizophrenia
EP4045009A4 (en) METHOD FOR TREATING BREAST CANCER
EP4003390A4 (en) METHOD FOR TREATING SOLID TUMORS
GB2590648B (en) Radiotherapy apparatus
GB201909466D0 (en) Compounds for treating cancer
GB201910244D0 (en) Method for treating cancer
GB201916968D0 (en) Means and method for treating cancer